PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

J&J moving to settle 1,000 talc lawsuits for more than $100M: Bloomberg

Battling more than 20,000 lawsuits alleging its talc powder causes cancer, Johnson & Johnson is moving to settle more than 1,000 suits for about $100 million, Bloomberg reports.

J&J, which hasn’t faced a talc trial in months amid the pandemic, used the slowdown to advance settlement negotiations, according to the news service. The company is inking settlements with numerous law firms representing more than 1,000 clients, the report said. 

“In certain circumstances, we do choose to settle lawsuits, which is done without an admission of liability and in no way changes our position regarding the safety of our products,” a J&J spokeswoman told Bloomberg. The company maintains its talc is “safe, does not contain asbestos and does not cause cancer.” 

The move comes as the number of talc cases against J&J has grown to more than 20,000 as of the company’s latest quarterly securities filing. Earlier this year, the company pulled talc powders from the market—citing a portfolio review—and launched cornstarch-based powders. 

J&J is normally “loathe to settle,” University of Richmond law professor Carl Tobias told Bloomberg, so the new group of deals signals a “strategy rather than a sign of desperation.” At times during its talc defense, the company has inked one-off settlements. 

It’d cost around $10 billion for J&J to settle all of its remaining talc lawsuits, Bloomberg Intelligence estimates. 

Meanwhile, it’s been months since the drugmaker was in a jury trial over talc claims, but that’s set to change next week as a trial starts up in California, Bloomberg reports. 

Over the course of its talc defense, numerous juries have ruled against the company; J&J has pledged to appeal in each case. A jury ordered the company to pay $4.7 billion in 2018, but J&J was able to reduce that amount to $2.1 billion after an appeal.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026